Abstract：Objective: To investigate the levels and significance of regulatory B cells (Breg), regulatory T cells (Treg) and their related cytokines in patients with immune thrombocytopenia (ITP) before and after treatment. Methods: A total of 103 ITP patients treated in our hospital from December 2018 to January 2022 were selected as the observation group, while 103 healthy volunteers were selected as the control group, and the two groups were examined for Breg cells, Treg cells, transforming growth factor-β (TGF-β), interleukin-10 (IL-10), interleukin-4 (IL-4), interleukin-17 ( IL-17), soluble programmed death 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) differences, and also analyze the differences of Breg cells and Treg cells before and after treatment in the observation group. Results: Breg cells, Treg cells, TGF-β, IL-10 and IL-4 in the observation group were (4.46±1.01)%, (5.11±1.03)%, (2203.19±225.51)pg/ml, (4.06±0.93)pg/ml and (298.32±55.62)pg/ml, respectively, which were significantly lower than those in the control group (P<0.05), IL-17 and sPD-1 were (12.01±2.28) pg/ml and (110.32±19.20) pg/ml, respectively, significantly higher than the control group (P<0.05). There was no statistically significant difference between the observation group and the control group comparing sPD-L1 (P>0.05). Breg cells, Treg cells, TGF-β, IL-10 and IL-4 were higher in the observation group 3 months after treatment compared with before treatment (P<0.05), while IL-17 and sPD-1 were lower than before treatment (P<0.05). The pre-treatment Breg cells and Treg cells were (3.88±0.97)% and (4.72±0.98)% in the observation group of treatment-ineffective patients, respectively, which were significantly lower than those of treatment-effective patients (P<0.05); the differences between the comparison of pre-treatment TGF-β, IL-10, IL-4, IL-17, sPD-1 and sPD-L1 in the observation group of treatment-ineffective and effective patients were not statistically (P>0.05). The post-treatment Breg cells, Treg cells and TGF-β were (5.68±1.01)%, (6.65±1.02)% and (2606.82±203.14)pg/ml, respectively, in the observation group of treatment-naive patients, which were significantly lower than those of treatment-effective patients (P<0.05), while IL-17 and sPD-1 were (10.11±1.60)pg/ml and (102.21±14.04) pg/ml, which were significantly higher than those in treatment effective patients (P<0.05). The area under the ROC curve for pre-treatment Breg cells and Treg cells predicting treatment effective was 0.694 and 0.725, respectively, P<0.05.Conclusion: Breg cells and Treg cells were significantly lower before treatment in ITP patients, and the levels of related cytokines were significantly abnormal. After treatment, the indices of Breg cells and Treg cells in patients improved significantly, while the pre-treatment Breg cells and Treg cells have some application value in predicting the efficacy of treatment.
郝立君, 许腾, 崔彦杰, 李智伟. ITP患者治疗前后Breg Treg构成及其相关细胞因子浓度变化和意义分析[J]. 河北医学, 2023, 29(5): 756-761.
HAO Lijun, XU Teng, CUI Yanjie, et al. Changes and Significance of Breg Treg Composition and Related Cytokine Concentration in ITP Patients before and after Treatment. HeBei Med, 2023, 29(5): 756-761.
[1] Bitsouni V,Tsilidis V.Mathematical modeling of tumor-immune system interactions:the effect of rituximab on breast cancer immune response[J].2022,539(8):111001. [2] Hanny Al-Samkari,Jiang D,Gernsheimer T,et al.Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim:a multicentre US study[J].British Journal of Haematology,2022,197(3):359-366. [3] Han P,Hou Y,Zhao Y,et al.Low-dose decitabine modulates T-cell homeostasis and restores immune tolerance in immune thrombocytopenia[J].Blood,2021,138(8):674-688. [4] Amit R.M,Aron K,Charina T,et al.Real-world use of fostamatinib in patients with immune thrombocytopenia and thrombotic risk[J].Acta Haematologica,2022,145(2):221-228. [5] Point F,Terriou L,Rakza T,et al.Risk factors for severe neonatal thrombocytopenia in cases of maternal immune thrombocytopenia[J].Acta paediatrica,2022,111(5):985-991. [6] 中华医学会血液学分会止血与血栓学组.成人原发免疫性血小板减少症诊断与治疗中国专家共识(2016年版)[C].2016. [7] 郭力,马道新,侯明.国际工作组免疫性血小板减少新分期标准与糖皮质激素疗效的关系[J].中华内科杂志,2010,49(12):4-5. [8] Frelinger A L,Grace R F,Gerrits A J,et al.Platelet function tests,independent of platelet count,are associated with bleeding severity in ITP[J].Blood,2021,126(7):873-879. [9] 于慧辉,詹延霞,季丽莉,等.原发性免疫性血小板减少症(ITP)患者CD5+B细胞对CD4+T细胞Th1/Th2型细胞因子分泌的影响[J].复旦学报(医学版),2020,47(1):53-58. [10] 李雪梅,邹东梅,孙雪静,等.外周血淋巴细胞亚群、Treg及细胞因子谱在不同病因血小板减少患者中的差异及意义[J].分子诊断与治疗杂志,2022,14(7):1237-1241. [11] 陈哲,张灵,刘洁,等.原发免疫性血小板减少症患者外周血CD4+T淋巴细胞表面PD-1表达水平分析[J].中国医药导报,2021,18(1):92-95. [12] 仲晓玲,吴文静.免疫性血小板减少症患者外周血Th17/Treg相关因子的表达及意义[J].川北医学院学报,2022,37(3):317-319+332. [13] 陈刚,谢文光,周京国,等.胸苷激酶1在痛风性关节炎、类风湿性关节炎和骨关节炎中的表达差异及临床意义[J].成都医学院学报,2021,16(6):730-733. [14] 李傲航,田媛媛,张金仿.原发免疫性血小板减少症患者血清细胞因子水平变化与血小板参数的相关性研究[J].临床和实验医学杂志,2021,20(15):1679-1681.
2023, Vol. 29 
冀公网安备13080202000677号